
    
      This study is a 13-week, open-label study of 8 participants with schizophrenia and minimal
      thought disorder; they will have 12 weeks of treatment and week for assessment. They will
      receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic
      treatment. The principal outcome measures will be the concentrations of the long and short
      forms of SDF1-Î± (stromal cell-derived factor alpha) in blood.
    
  